Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
Building on the academic medical center’s long history of surgical excellence, Dr. Donahue will focus on developing multidisciplinary programs that align patient care, research and education while fostering collaboration and discovery across the two institutions.
The National Institute on Aging of the National Institutes of Health has awarded a five-year grant initially worth $8.37 million for Weill Cornell Medicine researchers to study a new gene therapy for Alzheimer’s disease in people who have a high genetic risk of developing the condition. The research could garner nearly $14 million in total if prescribed milestones are reached for years three through five.
Researchers at Columbia University Irving Medical Center and Weill Cornell Medicine have won a $17.25 million grant from the Aligning Research to Understand Autism initiative to study profound autism, which affects over one quarter of individuals who are on the autism spectrum.
Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.
Over the last two decades, the Weill Cornell Community Clinic has become a bedrock of care for uninsured New Yorkers while also evolving into a deeply embedded part of medical education at Weill Cornell Medical College.
A recent paper examines the academic, economic and organizational forces jeopardizing a career as a physician-scientist and proposes a framework with the potential to both remedy and revitalize this unique workforce.
Dr. Gunisha Kaur has been appointed to the U.S. Commission on International Religious Freedom, an independent, bipartisan legislative branch agency that globally monitors the universal right to freedom of religion or belief.
A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.
A circuit that runs from the prefrontal cortex near the front of the brain to a deeper brain structure called the insular cortex appears to mediate the antidepressant effects of a newer form of transcranial magnetic stimulation (TMS), according to a study led by Weill Cornell Medicine investigators.
Extreme heat and cold are growing cardiovascular risks that can trigger heart attacks, strokes, heart failure and sudden cardiac death, according to a recent scientific statement by experts at Weill Cornell Medicine and other leading institutions.
The ASCERTAIN V clinical trial, led by Weill Cornell Medicine researchers, demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
A new cardiac magnetic resonance imaging-based measurement may improve how physicians assess a common heart valve condition, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Doctors should consider treating high cholesterol much earlier and more aggressively than they have in the past, according to a new perspective by Weill Cornell Medicine, NewYork-Presbyterian and Yale School of Medicine investigators.
Dr. Dhruv Khullar, an associate professor of population health sciences and of medicine at Weill Cornell Medicine, has been selected as an Emerging Leader in Health and Medicine (ELHM) Scholar by the National Academy of Medicine.
Underlying cardiovascular risk, rather than older age, drives complications such as venous thromboembolism, cardiomyopathy and heart failure during pregnancy, according to new Weill Cornell Medicine research.
Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most—but not all—of their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
